Document Detail


Heparins and venous thromboembolism: current practice and future directions.
MedLine Citation:
PMID:  11487039     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Unfractionated heparin (UFH) in adjusted doses and low-molecular-weight heparins (LMWH) in fixed doses are the chosen therapy for the initial treatment of venous thromboembolism. The use of UFH protocols ensures that virtually all patients will promptly achieve the therapeutic range for the activated partial thromboplastin time. However, proper use of UFH requires considerable expertise, can cause inconvenience and has limitations. Unmonitored therapy with subcutaneous LMWH is at least as effective and safe as adjusted-dose UFH, is associated with a considerable reduction of mortality in cancer patients, and permits the treatment of suitable patients in an outpatient setting. LMWH in high prophylactic doses is more effective than UFH and oral anticoagulants for prevention of postoperative venous thrombosis in major orthopedic surgery. Whether thromboprophylaxis should be continued for a few additional weeks after hospital discharge is controversial. LMWH and UFH are equally effective for prevention of postoperative deep-vein thrombosis in cancer patients. In a recent controlled randomized trial, enoxaparin in high prophylactic doses was an effective and safe measure of thromboprophylaxis in ordinary bedridden patients. The efficacy and safety of pentasaccharide (the smallest antithrombin binding sequence of heparin) in the treatment and prevention of venous thromboembolic disorders is currently under investigation.
Authors:
P Prandoni
Related Documents :
12232819 - Venous thromboembolism in cancer patients: expanding horizons.
2462069 - Palliation of painful bone metastases from prostate cancer using sodium etidronate: res...
20530049 - Congenital thrombophilia and central venous catheter-related thrombosis in patients wit...
21941099 - Active immunotherapeutics forum: advance phase iii active immunotherapy programs: just ...
12562049 - Future directions in the treatment and prevention of bone metastases.
15992459 - Clinical benefit of zoledronic acid for the prevention of skeletal complications in adv...
17714619 - Epithelial ovarian cancer surgical staging by ontario gynaecologic surgeons: is there a...
7565279 - Genetic susceptibility and occupational cancer.
22395309 - Expressions of putative cancer stem cell markers abcb1, abcg2, and cd133 are correlated...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  86     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-08-06     Completed Date:  2002-01-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  488-98     Citation Subset:  IM    
Affiliation:
Clinica Medica II, University of Padua, Italy. paoprand@tin.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Loss, Surgical
Fibrinolytic Agents / administration & dosage*,  adverse effects,  standards
Forecasting
Heparin / administration & dosage*,  adverse effects,  standards
Heparin, Low-Molecular-Weight / administration & dosage,  adverse effects,  standards
Humans
Thromboembolism / drug therapy*,  prevention & control
Venous Thrombosis / drug therapy*,  prevention & control
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism.
Next Document:  Thrombolysis in deep vein thrombosis: is there still an indication?